Sysmex Europe
Menu

March - Anti-platelet drugs mechanism

Blood platelets are activated by collagen released at the site of a vascular injury, by the change of blood flow (shear stress) and by thrombin formation. Platelets also increase their own activation by two mechanisms: the release of ADP and the thromboxane A2generation (TXA2), a potent platelet agonist. These mechanisms are also anti-platelet drugs’ main pharmacological targets: ADP receptor antagonists (thienopyridines) blockplatelet ADP receptors (P2Y12). Aspirin blocks cyclooxygenase (COX1), responsible for generating thromboxane A2 (TXA2). Sysmex’s CS-series coagulation analysers (exceptCS-1600) monitor anti-platelet drugs by Revohem reagents (ADP, arachidonic acid).

Copyright © Sysmex Europe GmbH. All rights reserved.

Cookie-Settings

We use cookies to enable you to optimally use our website and to improve our communication with you. We shall take your selection into account and use only the data for which you give us your consent.

These cookies help to make our website usable by enabling basic features such as page navigation and access to secure areas of our website. Our website cannot function properly without these cookies.

By collecting information anonymously, these cookies help us to understand how visitors interact with our website. This information enables us to continually improve our platform.

are used to track visitors on websites. The intention is to show advertisements that are relevant and appealing to the individual user and are, therefore, valuable to publishers and third-party advertisers.